Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

2.949

P-Index

This Author published in this journals

All Journal Cermin Dunia Kedokteran The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia Cermin Dunia Kedokteran

Juferdy Kurniawan

Divisi Hepatobilier, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Jakarta

Author-ID : 301892

Health Professions Medicine & Pharmacology Public Health

Published : 23 Documents Claim Missing Document

Claim Missing Document

Articles

1 2 3

Pilihan Tatalaksana Penyakit Perlemakan Hati Non-Alkohol (Non-Alcoholic Fatty Liver Disease/ NAFLD) Imanuel Setiawan, Stefanus; Kurniawan, Juferdy
Cermin Dunia Kedokteran Vol 48, No 3 (2021): Obstetri dan Ginekologi
Publisher : PT. Kalbe Farma Tbk.

Penyakit perlemakan hati non-alkohol (Non-alcoholic fatty liver disease/ NAFLD) merupakan kondisi adanya steatosis hepatik, inflamasi, dan kerusakan hepatosit (ballooning degeneration). NAFLD tidak hanya dianggap penyakit hati primer, tetapi juga merupakan bagian dari sindrom metabolik atau kondisi resistensi insulin dan penyakit terkait gaya hidup seperti diabetes, dislipidemia, dan hipertensi. Strategi tatalaksana NAFLD dimulai dari modifikasi gaya hidup, dapat dilanjutkan dengan terapi komponen sindrom metabolik, farmakoterapi, hingga penatalaksanaan sirosis.Non-alcoholic fatty liver disease refers to a steatosis in liver, associated with inflammation and destruction of hepatocyte (ballooning degeneration). NAFLD is considered as primary liver disease, but also as a component of metabolic syndrome related to insulin resistance and other life-style-related diseases i.e diabetes mellitus, dyslipidemia, and hypertension. Strategies in NAFLD management start with life-style modification, continued with pharmacological approaches targeting metabolic syndrome and complications related to cirrhosis.

The Role of Wisteria Floribunda (M2BPGi) Serum Level for Diagnosing Liver Fibrosis in Hepatitis B Patient: An Evidence Based Case Report Yosafat Lambang Prasetyadi; Agnes Elsha Maria Simbolon; Anggi Anggelina Permatasari; Dela Ryana Swaraghani; Shafira Chairunisa; Juferdy Kurniawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019
Publisher : The Indonesian Society for Digestive Endoscopy

Aim: To assess M2BPGi serum performance compared to liver biopsy in diagnosisng liver fibrosisMethod: Literature search using Pubmed®, Ebsco®, ProQuest®, Scopus®, Clinical Key databases, and the Cochrane Library® yield four relevant and full-text articles. The four articles were critically appraised for its validity, importance, and applicability.Results: Sensitivity and specificity in all four studies showed that M2BPGi serum was inadequate to ruling in and ruling out the diagnosis of liver fibrosis in chronic hepatitis B patients. The difference in M2BPGi cut-off value to determine the stage of fibrosis in each study makes this value cannot be used as an accurate standard to determine the advanced stage (F≥3) of liver fibrosis. On the other hand, M2BPGi serum combined with other tests are known to improve the diagnostic accuracy.Conclusion: MBP2Gi serum cannot be used as a diagnostic modality for detecting liver fibrosis in chronic hepatitis B patients.

Factors Associated with Surveillance for Early Detection of Hepatocellular Carcinoma in Liver Cirrhosis Patients Ario Perbowo Putra; Andri Sanityoso Sulaiman; Juferdy Kurniawan; Kuntjoro Harimurti
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Minimal number of KHS patients diagnosed through surveillance is thought to be the cause of continued low survival. It is important knowing the proportion of surveillance for early detection of KHS in patients with liver cirrhosis and related factors.Objective: Determine the proportion of surveillance for early detection of KHS in patients with liver cirrhosis and related factors.Method: Cross-sectional study of patients with liver cirrhosis at RSCM from January to December 2013. Data obtained from medical records and reconfirmed by telephone. Surveillance is required for abdominal ultrasound with or without AFP at least once a year within 3 years after that period. Factors studied were gender, ethnicity, education level, income level, availability of medical assurance, location of residence, surveillance education, cirrhosis etiology, and severity of cirrhosis. Then logistic regression test is used in the multivariate analysis.Results: From 200 patients, 50 patients (25,0%) underwent surveillance, 150 patients (75,0%) did not. Bivariate analysis resulted in 4 variables with p 0.25, gender (p = 0,056), ethnicity (p = 0, 231), surveillance education (p = 0,005), and severity of cirrhosis (p = 0, 005). Multivariate analysis resulted risk factors for surveillance were surveillance education (OR = 2,598; CI 95% (1,325 - 5,094), p = 0,005) and severity of cirrhosis (OR = 1.815; CI 95% = 1,210-2,724; p = 0,004).Conclusion: Surveillance education and severity of cirrhosis are factors associated with surveillance for early detection of KHS in liver cirrhosis patients.

Efficacy of Combination Sofosbuvir, Pegylated-Interferon, and Ribavirin for Treatment of Hepatitis C Virus Genotype 1 Infection in Indonesia Andri Sanityoso Sulaiman; Rino Alvani Gani; Irsan Hasan; Cosmas Rinaldi A Lesmana; Juferdy Kurniawan; Chyntia Olivia Maurine Jasirwan; Kemal Fariz Kalista; Muhammad Yusuf Hanif
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018
Publisher : The Indonesian Society for Digestive Endoscopy

Background: The presence of direct-acting antiviral (DAA) has improved the treatment of HCV infection and making it more preferable than Pegylated-interferon (PegIFN) and Ribavirin (RBV) based treatment. However, treatment with all DAA combination regimen is limited and expensive in low health care affordability country including Indonesia. The appearance of generic sofosbuvir (SOF) facilitate the utilization of SOF plus PegINF with or withour RBV combination. Therefore, in this study we assessed the efficacy of SOF+RBV and SOF+RBV+PegINF combination for treatment of chronic hepatitis C infections patient with genotype 1 in Indonesia.Method: We performed retrospective study comprising 128 patients in Cipto Mangunkusumo Hospital with chronic hepatitis C, genotype 1, infection. 36 patients was treated with PegINF+SOF+RBV and 92 patients was treated with SOF+RBV with the duration of therapy was 12 and 24 weeks in both arms. The primary endpoint was sustained virologic response after treatment completion (SVR12).Results: In the end of treatment, 99.2% patients achieved undetected HCV RNA in 12 weeks and 24 weeks duration of therapy (100% in PegINF+SOF+RBV group and 98.9% in SOF+RBV group). The SVR12 of PegINF+SOF+RBV reach 100% meanwhile The SVR12 of SOF+RBV reach 88%. No different in SVR12 between cirrhotic and non-cirrhotic patient in PegINF+SOF+RBV group while in SOF+RBV group, the SVR12 was lower in cirrhotic patients (82.9%) compared to non-cirrhotic patients (92.2%). In multivariate analysis, HIV co-infection is associated with lower SVR12 in SOF+RBV group.Conclusion: 12 weeks and 24 weeks of PegINF+SOF+RBV and SOF+RBV is effective in the treatment of genotype 1 chronic hepatitis C infection.

Survival COVID-19 in Adult Patients with Liver Cirrhosis Gita Aprilicia; Syahrizal Syarif; Kemal Fariz Kalista; Andri Sanityoso Sulaiman; Irsan Hasan; Cosmas Rinaldi A Lesmana; Juferdy Kurniawan; Chyntia Olivia Maurine Jasirwan; Saut Horas Hatoguan Nababan; Rino Alvani Gani
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021
Publisher : The Indonesian Society for Digestive Endoscopy

Background: COVID-19 is a disease caused by infection of SARS-CoV-2 virus which leads to mortality due to respiratory failure. The progression of COVID-19 is more severe in patients with pre-existence morbidities, including liver disease. Recently, a few studie showed that liver cirrhosis patients with COVID-19 had a higher risk of mortality rather than liver cirrhosis patients without COVID-19 infection. Nevertheless, the study of survival COVID-19 in a patient with underlying liver cirrhosis is still limited. The aim of this study is to evaluate the survival of COVID-19 in adult patients with liver cirrhosisMethod: An observational study in Cipto Mangunkusumo Hospital was conducted. Patients with underlying liver cirrhosis between March 2020-January 2021 with positive confirmation of COVID-19 were enrolled in this study. Liver cirrhosis patients without COVID-19 were enrolled as a comparison. Both liver cirrhosis patients with and without COVID-19 were follow up at the time of hospital admission until 30 days outcome. Kaplan Meier and a log-rank test were conducted to evaluate the comparison of survival rate in liver cirrhosis patients with and without COVID-19. Multivariate Cox Proportional Hazard was conducted to identify the independent risk factors related to survival.Results: There were 22 liver cirrhosis patients with COVID-19 and 116 liver cirrhosis patients included in this study. Presentation of gender and age similar both of them. Predominantly males with average age were 57 years ± 13,60 for cirrhosis with COVID-19 patients and 53 years ± 12,75 for without COVID-19. The survival rate of liver cirrhosis patients with COVID-19 lower than liver cirrhosis patients without COVID-19 (35.8% vs. 67.2%, p-value 0.001). Median survival of liver cirrhosis patients with COVID-19 was 4 days (95% CI: 1-8 days), while median survival of liver cirrhosis patients without COVID-19 couldn’t be reached since the survival rate of this group above 50%. Final model Cox PH showed that liver cirrhosis with COVID-19 (HR: 8.99; CI 95%: 4.55 – 17.80, p-value 0.001) and Child-Pugh class C (HR: 5.61; 95% CI: 2.76 – 11.40, p-value 0.001) were the independent risk factors associated with poor survival.Conclusion: The survival rate of liver cirrhosis patients with COVID-19 lower than liver cirrhosis patients without COVID-19. Liver cirrhosis with COVID-19 and Child-Pugh class C were associated with poor survival.

Diarrhea in HIV Infection Juferdy Kurniawan; Marcellus Simadibrata; Teguh Karyadi; Kie Chen
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 10, ISSUE 1, April 2009
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/101200923-28

During the last decade, there has been an increase of immunocompromized patients all around the world; that mostly due to pandemic of Human Immunodeficiency Virus (HIV) infection. Chronic diarrhea as one of common symptoms in patients with HIV infection has different etiology compared to immunocompetent patients. Initial approach of diarrhea in HIV infection may be conducted by evaluating the temporal relationship between the development of diarrhea and the administration of antiretroviral, especially the protease inhibitor agents; which is then followed by fecal analysis/examination for pathogenic bacteria and protozoa as well as endoscopy examination. Biopsy examination of intestinal mucosa is necessary for HIV enteropathy or diarrhea due to microsporidia, which is confirmed further by electron microscopy. The etiology of chronic diarrhea in HIV patients may also different, depend on the cluster of differentiation count value of all patients. Based on such differences, it is necessary to have adequate approach, recognition and understanding in the management of chronic diarrhea, especially for HIV patients. Keywords: diarrhea, infection, HI

Liver Support System and Transplant-Free Survival Patients with Liver Failure: An Evidence-Based Case Report Aravinda Pravita; Kresna Adhiatma; Juferdy Kurniawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Background: The mortality rate in patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF) is still very high. Currently, liver support systems are an alternative therapy in bridging liver transplantation. However, its effectiveness in reducing mortality is still controversial when compared to standard medical therapy (SMT). Our study aims to review the efficacy of liver support system compared to standard medical therapy (SMT) among acute liver failure patients without liver transplantation.Method: We conducted systematic literature searching using PubMed/MEDLINE, EBSCO-CINAHL, ProQuest, and Cochrane databases. Selected articles were examined for duplicates and were screened by abstract and title. Then, we appraised the articles based on the critical appraisal tools from Centre for Evidence-Based Medicine (CEBM) University of OxfordResults: One systematic review and meta-analysis of randomized control trials study was extracted after thorough research. Alhamshi et al showed that extracorporeal liver support has significantly reduced mortality in both ALF and ACLF patients as the primary outcome. Other main findings about adverse events including hepatic encephalopathy, thrombocytopenia, bleeding, and infection were still unclear.Conclusion: The use of liver support system demonstrated better outcome in reducing mortality to standard medical therapy in transplant free patients with liver failure, but best modality recommendation was inconclusive.

Liver Transplant in Hepatocellular Carcinoma: Indication and Prognostic Factors Gunawan - -; Irsan Hasan; Juferdy Kurniawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. There are several treatment modalities according to Barcelona treatment algorithm. Liver transplant is one of the curative option treatments, with its indication and prognostic factors. Carefully selected patients for liver transplant in HCC case will result in the same or slightly inferior survival rate compare with liver transplant in non-malignancy case.

Tumor Response Evaluation Transarterial Chemoembolization-treated Hepatocellular Carcinoma Juferdy Kurniawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016
Publisher : The Indonesian Society for Digestive Endoscopy

Pangenotypic Direct Acting Antivirals Treatment for Chronic Hepatitis C Infection Juferdy Kurniawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020
Publisher : The Indonesian Society for Digestive Endoscopy

Co-Authors -, Gunawan - -, Gunawan - A, GM Yudi Prasetia Agnes Elsha Maria Simbolon Amin, Bany Faris Andhika Rachman Andri Sanityoso Andri Sanityoso Sulaiman Anggi Anggelina Permatasari Aprilicia, Gita Aravinda Pravita Ario Perbowo Putra Ario Perbowo Putra, Ario Perbowo Aulia Rizka, Aulia Baiq Kirana DN Mandasari Bany Faris Amin Budiman, Refael Alfa C Rinaldi A Lesmana Chairunisa, Shafira Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Cleopas Martin Rumende Dadang Makmun Dela Ryana Swaraghani Dewi ANGGRAENI Dewi Martalena Diana Sunardi E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Esthika Dewiasty, Esthika Felix Firyanto Widjaja Gita Aprilicia GM Yudi Prasetia A Gunawan - - Hanif, Muhammad Yusuf Hasan Maulahela, Hasan Ikhwan Rinaldi Imanuel Setiawan, Stefanus Irfan Kresnadi Irfan Kresnadi Irsan Hasan Jasirwan, Chyntia Olivia M Karenina, Vannessa Kemal F Calista Kemal Fariz Kalista Kemal Fariz Kalista Kemal Fariz Kalista, Kemal Fariz Kie Chen Kresna Adhiatma Kresnadi, Irfan Kuntjoro Harimurti Kurniyanto Kurniyanto Kurniyanto, Kurniyanto Leonard Nainggolan Lutfie Lutfie, Lutfie Marcellus Simadibrata Marcellus Simadibrata Muhammad Yusuf Hanif Nababan, Saut Horas H. Nadia Ayu Mulansari, Nadia Ayu Permatasari, Anggi Anggelina Prasetyadi, Yosafat Lambang Purwita Wijaya Laksmi Putra Nur Hidayat Putri, Trivani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rudy Hidayat Sakinah Rahma Sari Sari, Sakinah Rahma Saut HH Nababan Saut Horas Hatoguan Nababan Sepmeitutu, Iwandheny Shafira Chairunisa Siahaan, Billy Stinggo Simbolon, Agnes Elsha Maria Stefanus Imanuel Setiawan Swaraghani, Dela Ryana Syahrizal Syarif Tahir, Andi Cahaya Teguh Karyadi Teressa, Maria Trivani Putri Triyanta Yuli Pramana Vannessa Karenina Widayat Djoko Santoso Widayat Djoko Santoso, Widayat Djoko Yosafat Lambang Prasetyadi

Title

Found 23 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 23 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 23 Documents
Search